⌕
Cogent Biosciences · COGT · Nasdaq
Tenet 33 · Weak
Compare
$27.44−3.92%At closeTenet 33 · Weak
$27.44−1.12 (−3.92%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Cogent Biosciences (COGT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is COGT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● GlobeNewsWireOct 27, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

WALTHAM, Mass. and BOULDER, Colo.…

COGT −3.9% todayRead at source ↗
● Defense WorldOct 1, 2026 · 04:29 ET
Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56

Cogent Biosciences, Inc. (NASDAQ: COGT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One i…

COGT −3.9% todayRead at source ↗
● GlobeNewsWireSep 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM…

COGT −3.9% todayRead at source ↗
● Seeking AlphaAug 27, 2026 · 08:24 ET
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat

Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three N…

COGT −3.9% todayRead at source ↗
● Defense WorldAug 24, 2026 · 04:18 ET
Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT

Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during a recent quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 266,584 shar…

COGT −3.9% todayRead at source ↗
● Defense WorldAug 18, 2026 · 03:38 ET
Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGT

Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commissi…

COGT −3.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just COGT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.